Cargando…

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study

Detalles Bibliográficos
Autores principales:	Maxfield, LF, King, SL, Riggs, AM, Dilan, R, LaPorte, A, Hural, J, McElrath, MJ, Goudsmit, J, Barouch, DH
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767809/ http://dx.doi.org/10.1186/1742-4690-6-S3-P304

Ejemplares similares

Development of replication-competent adenovirus based vaccine vectors
por: Abbink, P, et al.
Publicado: (2012)

P17-13. Hexon hypervariable regions 4–7 contain important Ad5-specific neutralizing antibody epitopes
por: Bradley, RR, et al.
Publicado: (2009)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Adenovirus vectors from various serotypes induce distinct cytokine profiles
por: Teigler, JE, et al.
Publicado: (2012)

Winning grants step by step: the complete workbook for planning, developing, and writing successful proposals
por: O'Neal-McElrath, Tori, et al.
Publicado: (2013)

Use of adenovirus type-5 vectored vaccines: a cautionary tale
por: Buchbinder, Susan P, et al.
Publicado: (2020)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

P10-06. Adaptive immune responses elicited by recombinant adenovirus vectors exhibit partial MyD88 dependence
por: Rhee, EG, et al.
Publicado: (2009)

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

P19-48. Induction of Ad5 neutralizing antibodies in placebo recipients during the Step Trial is not associated with risk of HIV infection
por: Spies, G, et al.
Publicado: (2009)

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

Different memory T cell phenotypes are elicited by Ad5 and rare adenoviruses
por: Penaloza, P, et al.
Publicado: (2012)

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
por: Li, H, et al.
Publicado: (2012)

Low Seroprevalent Species D Adenovirus Vectors as Influenza Vaccines
por: Weaver, Eric A., et al.
Publicado: (2013)

Seroprevalence of human adenovirus type 5 neutralizing antibodies in the Philippines
por: Francisco, Abialbon G., et al.
Publicado: (2023)

Emergent Electroweak Gravity
por: McElrath, Bob
Publicado: (2008)

Laboratory tests for the cosmic neutrino background using beta-decaying nuclei
por: McElrath, Bob
Publicado: (2009)

On The Origin of Neutrino Mass and Mixing in the Standard Model
por: McElrath, Bob
Publicado: (2009)

Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients
por: Zhao, Hua, et al.
Publicado: (2018)

$h \to \mu^{+}\mu^{-}$ via Gluon Fusion at the LHC
por: Han, T, et al.
Publicado: (2002)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization
por: Maxfield, Lori F., et al.
Publicado: (2015)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

There is no explosion risk associated with superfluid Helium in the LHC cooling system
por: Fairbairn, Malcolm, et al.
Publicado: (2008)

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
por: Rolland, M, et al.
Publicado: (2009)

Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
por: O’Brien, Kara L., et al.
Publicado: (2009)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China
por: Zheng, Xuehua, et al.
Publicado: (2017)

Comparative biological characterization of mouse adenovirus strains FL and K 87 and seroprevalence in laboratory rodents
por: Smith, A. L., et al.
Publicado: (1986)

Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders
por: Klann, Patrick Julian, et al.
Publicado: (2022)

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial
por: Fellay, J, et al.
Publicado: (2009)

Use of B-Cell–Depleting Therapy in Women of Childbearing Potential With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
por: Galati, Alexandra, et al.
Publicado: (2022)

Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles
por: Migueles, Stephen A., et al.
Publicado: (2011)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Novel immunological strategies for HIV-1 eradication
por: Jülg, B, et al.
Publicado: (2015)

Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2012)

22 Levertransplantatie
por: van Hoek, B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mqjihsb0mfb6vg8u0c1d3p0m1j